NASDAQ:CYTK Cytokinetics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytokinetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.87 -0.94 (-4.31 %) (As of 09/21/2020 02:39 PM ET) Add Compare Share Today's Range$20.19Now: $20.87▼$21.3850-Day Range$21.08MA: $22.90▼$24.7352-Week Range$7.72Now: $20.87▼$29.20Volume25,051 shsAverage Volume915,295 shsMarket Capitalization$1.47 billionP/E RatioN/ADividend YieldN/ABeta1.46 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.6 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.38, Cytokinetics has a forecasted upside of 86.8% from its current price of $21.08.Amount of Analyst CoverageCytokinetics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.5 Community Rank Outperform VotesCytokinetics has received 684 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytokinetics has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytokinetics has received 70.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote “Outperform” if you believe CYTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,112,424.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Cytokinetics is held by insiders.Percentage Held by Institutions81.86% of the stock of Cytokinetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($2.30) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.6Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.94 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTK Previous Symbol CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone650-624-3000Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.87 million Price / Sales54.76 Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-109.84Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-121,690,000.00 Net Margins-751.39% Return on EquityN/A Return on Assets-58.12%Miscellaneous Employees130 Outstanding Shares70,505,000Market Cap$1.47 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $20.87 -0.94 (-4.31 %) (As of 09/21/2020 02:39 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CYTK News and Ratings via Email Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions How has Cytokinetics' stock price been impacted by COVID-19 (Coronavirus)? Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 73.5% and is now trading at $20.87. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cytokinetics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics. When is Cytokinetics' next earnings date? Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Cytokinetics. How were Cytokinetics' earnings last quarter? Cytokinetics, Inc. (NASDAQ:CYTK) posted its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.11. The biopharmaceutical company had revenue of $3.59 million for the quarter, compared to the consensus estimate of $4.80 million. View Cytokinetics' earnings history. What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $24.38 million. What price target have analysts set for CYTK? 8 equities research analysts have issued 1-year price targets for Cytokinetics' stock. Their forecasts range from $29.00 to $59.00. On average, they expect Cytokinetics' share price to reach $39.38 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts' price targets for Cytokinetics. Who are some of Cytokinetics' key competitors? Some companies that are related to Cytokinetics include Bausch Health Companies (BHC), Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), MorphoSys (MOR), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Allakos (ALLK), Arena Pharmaceuticals (ARNA), Evotec (EVTCY) and FibroGen (FGEN). View all competitors. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), TherapeuticsMD (TXMD) and Sorrento Therapeutics (SRNE). Who are Cytokinetics' key executives? Cytokinetics' management team includes the following people: Mr. Robert I. Blum, CEO, Pres & Director (Age 55)Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59) What is Cytokinetics' stock symbol? Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK." Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.48%), FMR LLC (4.98%), Wasatch Advisors Inc. (4.81%), Great Point Partners LLC (2.16%), Logos Global Management LP (1.13%) and Two Sigma Advisers LP (1.03%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics. Which institutional investors are selling Cytokinetics stock? CYTK stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Vanguard Group Inc., Wasatch Advisors Inc., Hudson Bay Capital Management LP, ClariVest Asset Management LLC, SG Americas Securities LLC, and Russell Investments Group Ltd.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics. Which institutional investors are buying Cytokinetics stock? CYTK stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Logos Global Management LP, FMR LLC, Opaleye Management Inc., Sofinnova Investments Inc., Bank of America Corp DE, EAM Investors LLC, and Barclays PLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics. How do I buy shares of Cytokinetics? Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cytokinetics' stock price today? One share of CYTK stock can currently be purchased for approximately $20.87. How big of a company is Cytokinetics? Cytokinetics has a market capitalization of $1.47 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. What is Cytokinetics' official website? The official website for Cytokinetics is www.cytokinetics.com. How can I contact Cytokinetics? Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
